SUBSCRIBE
SUBSCRIBE
News   Business

Kyowa Hakko Kogyo Co., Ltd. Licenses Anticancer Agent KW-2401 To Keryx Biopharmaceuticals

October 4, 2006 | 
1 min read

Tokyo, Oct 4, 2006 (JCN) - Kyowa Hakko Kogyo entered into a license agreement with US-based Keryx Biopharmaceuticals on September 29 for Kyowa’s original anticancer agent KW-2401 (UCN-01).

Alliances Asia
MORE ON THIS TOPIC
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Cellectar Downsizes by 60% as it Explores Strategic Options for Cancer Drug
December 11, 2024
 · 
202 min read
 · 
BioSpace Editorial Staff
Podcast
Highlights From ASH, Lilly and Novo’s Manufacturing Boon, Momentum in Neuro, More
December 11, 2024
 · 
1 min read
 · 
Heather McKenzie
Group Of Employees Being Fired By Their Company.
Layoffs
Carisma Therapeutics to Cut 34% of Staff, Reprioritize Pipeline
December 10, 2024
 · 
2 min read
 · 
Angela Gabriel
Correct decision chosing - confused man character standing on the crossroads and looking at signpost with three different directions - conceptual vector illustration
Depression
Relmada Considering ‘Strategic Alternatives’ After Failure of Depression Asset
December 9, 2024
 · 
1 min read
 · 
Heather McKenzie